Antares Pharma Stock Forecast for 2023 - 2025 - 2030

Updated on 01/31/2023

Stock Rating
8
Price Target
$5.25
Consensus
-
Downside
-6.08%
Analysts
2
Stock Rating
8
Downside
-6.08%
Analysts
2
Price Target
$5.25

Antares Pharma Stock Forecast and Price Target

If the average 2023 price target of $5.25 recently set by two prominent experts for Antares Pharma is met, there would be a potential downside of approximately -6.08% from the last closing price in May, 2022. The high estimate is $5.89, and the low is $4.68. If you're interested in investing in this company, why not also look at its competitors to see how they are doing?

$5.25

-6.08% Downside

-

Antares Pharma Fair Value Forecast for 2023 - 2025 - 2030

In the last two years, Antares Pharma's Price has grown, moving from $0.00 to $1.79 – an increase of 100.00%. According to 0 analysts, Antares Pharma's Fair Value will fall by 65.56% in the next year, reaching $0.61. Professionals believe that By 2030, Antares Pharma's Fair Value will fall to $1.17 – a 34.23% decrease from its current value.

2022 Fair Value Forecast
$0.61
2023 Fair Value Forecast
$0.68
2024 Fair Value Forecast
$1.00
2025 Fair Value Forecast
$1.50
2026 Fair Value Forecast
$1.12
2027 Fair Value Forecast
$1.01
2028 Fair Value Forecast
$1.05
2029 Fair Value Forecast
$1.19
2030 Fair Value Forecast
$1.17
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
LLY Stock Forecast Eli Lilly and Outperform 16
$344.15 $333.19 16.23%
ABBV Stock Forecast AbbVie Outperform 10
$147.74 $162.12 11.68%
PFE Stock Forecast Pfizer Inc Outperform 3
$44.16 $53.97 19.23%
CVS Stock Forecast CVS Health Corp Outperform 13
$88.23 $115.94 30.96%
GSK Stock Forecast GSK Hold 16
£1.42k £16.95 -98.87%

Antares Pharma Revenue Forecast for 2023 - 2025 - 2030

In the last two years, Antares Pharma's Revenue has grown, moving from $123.86M to $183.98M – an increase of 48.54%. According to 0 analysts, Antares Pharma's Revenue will fall by 18.20% in the next year, reaching $150.50M. Professionals believe that By 2030, Antares Pharma's Revenue will fall to $154.77M – a 15.88% decrease from its current value.

2022 Rev Forecast
$0.15B
2023 Rev Forecast
$0.14B
2024 Rev Forecast
$0.15B
2025 Rev Forecast
$0.16B
2026 Rev Forecast
$0.16B
2027 Rev Forecast
$0.15B
2028 Rev Forecast
$0.15B
2029 Rev Forecast
$0.15B
2030 Rev Forecast
$0.15B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
SUNPHARMA Stock Forecast Sun Pharmaceutical Industries Outperform 18
Rp1.01k Rp845.39 2.61%
WST Stock Forecast West Pharmaceutical Services Outperform 18
$265.60 $402.50 -3.99%
VTRS Stock Forecast Viatris Outperform 8
$12.15 $13.70 11.11%

Antares Pharma Dividend per Share Forecast for 2023 - 2025 - 2030

Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
TEVA Stock Forecast Teva Pharmaceutical Industries Hold 12
$10.54 $12.04 -5.12%
PRGO Stock Forecast Perrigo Buy 16
$37.42 $47.75 26.94%
4183 Stock Forecast Mitsui Chemicals Hold 18
¥2.99k ¥0.00 30.65%

Antares Pharma Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last two years, Free Cash Flow for Antares Pharma has grown by 331.30%, going from $-12.97M to $30.00M. For the following year, the 0 analysts predict that Antares Pharma's Free Cash Flow will drop by 110.95%, reaching $-3.29M. In 2030, the professionals' prediction is that NasdaqCM:ATRS's Free Cash Flow will decrease by 478.30%, reaching $-113.49M.

2022 FCF Forecast
$-3285000.00
2023 FCF Forecast
$-11403220.50
2024 FCF Forecast
$-44892578.57
2025 FCF Forecast
$-174699469.51
2026 FCF Forecast
$-46534115.36
2027 FCF Forecast
$-66159102.95
2028 FCF Forecast
$-103971235.59
2029 FCF Forecast
$-176539692.32
2030 FCF Forecast
$-113491483.53
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
YPSN Stock Forecast Ypsomed Holding Outperform 18
CHF131.20 CHF154.00 44.82%
ENDP Stock Forecast Endo International Underperform 14
$0.41 $0.00 143.90%
ALCJ Stock Forecast Crossject Société Anonyme Sell 9
3.09€ 1.70€ 107.12%

Antares Pharma Net Income Forecast for 2023 - 2025 - 2030

Antares Pharma's Net Income has seen growth In the last two years, going from $-2.03M to $46.29M – a gain of 2380.30% 0 analysts predict Antares Pharma's Net Income will decrease by 20.26% in the next year, reaching $36.91M. By 2030, professionals predict that Antares Pharma's Net Income will decrease by 16.41%, to $38.70M.

2022 NI Forecast
$0.04B
2023 NI Forecast
$0.03B
2024 NI Forecast
$0.04B
2025 NI Forecast
$0.04B
2026 NI Forecast
$0.04B
2027 NI Forecast
$0.04B
2028 NI Forecast
$0.04B
2029 NI Forecast
$0.04B
2030 NI Forecast
$0.04B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
MDP Stock Forecast Medexus Pharmaceuticals Outperform 0
C$2.80 C$0.00 96.43%
ASP Stock Forecast Acerus Pharmaceuticals - 0
C$2.83 C$0.00 9.19%
BMY Stock Forecast Bristol-Myers Squibb Co Outperform 2
$72.51 $80.99 14.47%

Antares Pharma EBITDA Forecast for 2023 - 2025 - 2030

Antares Pharma's EBITDA has grown in the last two years, jumping from $3.55M to $31.24M – an increase of 780.00%. In the following year, the 0 analysts surveyed believe that Antares Pharma's EBITDA will decrease by 58.04%, reaching $13.11M. According to professionals, by 2030, Antares Pharma's EBITDA will have decreased by 35.69%, falling down to $20.09M.

2022 EBITDA Forecast
$0.01B
2023 EBITDA Forecast
$0.01B
2024 EBITDA Forecast
$0.02B
2025 EBITDA Forecast
$0.02B
2026 EBITDA Forecast
$0.02B
2027 EBITDA Forecast
$0.02B
2028 EBITDA Forecast
$0.02B
2029 EBITDA Forecast
$0.02B
2030 EBITDA Forecast
$0.02B

Antares Pharma EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Antares Pharma's EBIT has increased by 2661.62%, going from $990.00k to $27.34M. The next year, 0 experts forecast that Antares Pharma's EBIT will decrease by 64.36%, reaching $9.74M. In 2030, professionals predict that Antares Pharma's EBIT will decrease by 34.73%, reaching $17.85M.

2022 EBIT Forecast
$0.01B
2023 EBIT Forecast
$0.01B
2024 EBIT Forecast
$0.02B
2025 EBIT Forecast
$0.02B
2026 EBIT Forecast
$0.02B
2027 EBIT Forecast
$0.02B
2028 EBIT Forecast
$0.02B
2029 EBIT Forecast
$0.02B
2030 EBIT Forecast
$0.02B

Antares Pharma EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last two years, Antares Pharma's EPS has grown, moving from $-0.01 to $0.10 – an increase of 1100.00%. According to 0 analysts, Antares Pharma's EPS will fall by 65.56% in the next year, reaching $0.03. Professionals believe that By 2030, Antares Pharma's EPS will fall to $0.07 – a 34.23% decrease from its current value.

2022 EPS Forecast
$0.03
2023 EPS Forecast
$0.04
2024 EPS Forecast
$0.06
2025 EPS Forecast
$0.08
2026 EPS Forecast
$0.06
2027 EPS Forecast
$0.06
2028 EPS Forecast
$0.06
2029 EPS Forecast
$0.07
2030 EPS Forecast
$0.07